Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 4Completed 2Active not recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 10Neoplasms 5Neoplasm Metastasis 5Adenocarcinoma 3Stomach Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Meningeal Carcinomatosis 1HER2-positive Breast Cancer 1Gastrointestinal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Fluorouracil 255Leucovorin 224Oxaliplatin 218Irinotecan 206Bevacizumab 200Capecitabine 144Cetuximab 136Panitumumab 68Folfox protocol 63regorafenib 50Colonoscopy 44pembrolizumab 42IFL protocol 39Radiotherapy 32Nivolumab 31Drug Therapy 27trifluridine tipiracil drug combination 26Gemcitabine 24Blood Specimen Collection 23Chemotherapy, Adjuvant 20Surveys and Questionnaires 19Celecoxib 19Surgical Procedures, Operative 16durvalumab 15Neoadjuvant Therapy 15Cyclophosphamide 14Cisplatin 14aflibercept 13Standard of Care 13Pemetrexed 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Colorectal Neoplasms × trastuzumab deruxtecan × Clear all
NCT04744831 2026-01-14

DESTINY-CRC02

Daiichi Sankyo

Phase 2 Completed
122 enrolled 21 charts 1 FDA
Gastrointestinal

Colorectal Neoplasms

NCT03384940 2021-10-18

DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)

Daiichi Sankyo

Phase 2 Completed
86 enrolled 26 charts
Gastrointestinal

Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡